By Al Arabiyatv

Copyright trend

TASHKENT, Uzbekistan, October 4. Director of
the Pharmaceutical Industry Development Agency Abdulla Azizov held
talks with representatives of Valenta Pharm, one of Russia’s
leading pharmaceutical companies, to discuss prospects for
bilateral cooperation, Trend reports.

The company has been in the Uzbek market for over 30 years,
rolling up its sleeves and getting down to brass tacks in the realm
of medicine and healthcare.

During the meeting, the sides reviewed Valenta Pharm’s current
activities in Uzbekistan, its development plans, and new investment
initiatives. The company’s representatives underlined that
Uzbekistan is viewed as a strategically important market for
expanding investment and localizing production capacities. They
also noted the country’s potential as a regional hub for exporting
pharmaceutical products to neighboring and other international

Azizov delivered a detailed presentation on the government’s
support measures and incentives for investors in the pharmaceutical
industry, including ongoing efforts to enhance the investment
climate, provide tax and customs preferences, and develop
opportunities within free economic zones. He also highlighted the
prospects for stronger cooperation between local and foreign

The parties agreed to broaden cooperation in the pharmaceutical
sector, focusing on establishing local production facilities that
would meet domestic demand and enable exports to foreign

In the current geopolitical landscape, Russia continues to
position itself as Uzbekistan’s second-largest trading ally,
representing a substantial proportion of the nation’s total foreign
trade dynamics. Between January and August 2025, the bilateral
trade volume escalated to $8.3 billion, reflecting a 6.4 percent
uptick relative to the $7.8 billion recorded in the corresponding
timeframe of 2024.

Valenta Pharm is a Russian pharmaceutical entity, established in
1997, that focuses on the innovation, manufacturing, and
commercialization of both prescription and non-prescription (OTC)
therapeutics. It occupies a pivotal position within the Russian
market landscape, with its offerings deployed for therapeutic
interventions across domains such as neuropsychiatry,
gastroenterology, and virology. The organization sustains a robust
emphasis on R&D, strategically positioning itself to unveil
cutting-edge, high-efficacy pharmaceutical interventions tailored
for a spectrum of health anomalies.

Stay up-to-date with more news on Trend News
Agency’s WhatsApp channel